Status:

COMPLETED

Prevention of Renal Failure by Nitric Oxide in Prolonged Cardiopulmonary Bypass.

Lead Sponsor:

Xijing Hospital

Conditions:

Heart Valve Diseases

Heart; Complications, Valve, Prosthesis

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

Prolonged periods of cardiopulmonary bypass (CPB) cause high levels of plasma free haemoglobin(Hb) and are associated with increased morbidity. We hypothesized that repletion of nitric oxide (NO) duri...

Detailed Description

Prolonged periods of cardiopulmonary bypass (CPB) cause high levels of plasma free haemoglobin(Hb) and are associated with increased morbidity. We hypothesized that repletion of nitric oxide (NO) duri...

Eligibility Criteria

Inclusion

  • Provide written informed consent
  • Are \> 18 years of age
  • Elective cardiac or aortic surgery with CPB, when the surgeon plans double valve replacement.
  • Stable pre-operative renal function, without dialysis.

Exclusion

  • Emergent cardiac surgery
  • Life expectancy \< 1 year
  • Hemodynamic instability as defined by a systolic blood pressure \<90 mmHg
  • Administration of ≥1 Packed Red Blood Cell transfusion in the week before surgery
  • X-ray contrast infusion less than 1 week before surgery
  • Anticipate administration of nephrotoxic agents, such as hydroxyethyl starch
  • Evidence of intravascular or extravascular hemolysis

Key Trial Info

Start Date :

August 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2016

Estimated Enrollment :

217 Patients enrolled

Trial Details

Trial ID

NCT01802619

Start Date

August 1 2013

End Date

June 1 2016

Last Update

February 13 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xijing Hospital

Xi'an, Shaanxi, China, 710032